Genetron Holdings Limited (GTH)
| Market Cap | 112.11M |
| Revenue (ttm) | 93.36M |
| Net Income (ttm) | -115.98M |
| Shares Out | 30.46M |
| EPS (ttm) | -3.69 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 12,498 |
| Open | 3.70 |
| Previous Close | 3.70 |
| Day's Range | 3.66 - 3.70 |
| 52-Week Range | 2.08 - 3.81 |
| Beta | 0.47 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Jan 9, 2024 |
About GTH
Genetron Holdings Limited, a precision oncology platform company, focuses on cancer management by utilizing technologies in molecular biology and data science in the People's Republic of China. It offers diagnosis and monitoring services, and early screening services through laboratory developed tests services. The company also provides in-vitro diagnostic products, including 8-gene lung cancer assay, an IVD assay product to detect lung cancer; Genetron 3D biochip reading instrument; Genetron S5, a semiconductor-based NGS system, which detects ... [Read more]
Financial Performance
In 2022, GTH's revenue was 650.71 million, an increase of 22.32% compared to the previous year's 531.95 million. Losses were -808.40 million, 62.9% more than in 2021.
Financial numbers in CNY Financial StatementsNews
Genetron Health Enters into Definitive Merger Agreement for Going Private Transaction
BEIJING, Oct. 11, 2023 (GLOBE NEWSWIRE) -- Genetron Holdings Limited (“Genetron Health” or the “Company”, NASDAQ: GTH), a leading precision oncology platform company in China that specializes in offer...
Genetron Health Announces Receipt of Notification from Nasdaq
BEIJING, May 23, 2023 (GLOBE NEWSWIRE) -- Genetron Holdings Limited ("Genetron Health" or the "Company", NASDAQ: GTH), a leading precision oncology platform company in China that specializes in offeri...
Genetron Health Regains Compliance With Nasdaq Minimum Bid Price Requirement
BEIJING, Jan. 18, 2023 (GLOBE NEWSWIRE) -- Genetron Holdings Limited ("Genetron Health" or the "Company", NASDAQ: GTH), a leading precision oncology platform company in China that specializes in offer...
Genetron Health Reports Unaudited Second Quarter 2022 Financial Results
BEIJING, Oct. 12, 2022 (GLOBE NEWSWIRE) -- Genetron Holdings Limited ("Genetron Health" or the "Company", NASDAQ: GTH), a leading precision oncology platform company in China that specializes in offer...
Genetron Health Announces Appointment of Independent Financial Advisor and Legal Counsel to the Special Committee
BEIJING, Sept. 02, 2022 (GLOBE NEWSWIRE) -- Genetron Holdings Limited (“Genetron Health” or the “Company”, NASDAQ: GTH), a leading precision oncology platform company in China that specializes in offe...
Genetron Health Announces Receipt of a Preliminary Non-Binding Proposal to Acquire the Company
BEIJING, Aug. 22, 2022 (GLOBE NEWSWIRE) -- Genetron Holdings Limited (“Genetron Health” or the “Company”, NASDAQ: GTH), a leading precision oncology platform company in China that specializes in offer...
Genetron Health to Participate in the Goldman Sachs Healthcare Corporate Day
BEIJING, June 16, 2022 (GLOBE NEWSWIRE) -- Genetron Holdings Limited (“Genetron Health” or the “Company”, Nasdaq: GTH), a leading precision oncology platform company in China that specializes in offer...
Genetron Health Receives CAP Accreditation for its Maryland Laboratory
BEIJING, June 15, 2022 (GLOBE NEWSWIRE) -- Genetron Holdings Limited (“Genetron Health” or the “Company”, NASDAQ: GTH), a leading precision oncology platform company in China that specializes in offer...
Genetron Health Reports Unaudited First Quarter 2022 Financial Results
BEIJING, June 02, 2022 (GLOBE NEWSWIRE) -- Genetron Holdings Limited (“Genetron Health” or the “Company”, NASDAQ: GTH), a leading precision oncology platform company in China that specializes in offer...
Genetron Health Releases 10 New Research Results at 2022 American Society of Clinical Oncology (ASCO) Annual Meeting
BEIJING, June 02, 2022 (GLOBE NEWSWIRE) -- Genetron Holdings Limited (“Genetron Health” or the “Company”, Nasdaq: GTH), a leading precision oncology platform company in China that specializes in offer...
Genetron Health Receives CE Mark for FusionScan Plus Kit for Human Multi-Genes
BEIJING, June 01, 2022 (GLOBE NEWSWIRE) -- Genetron Holdings Limited (“Genetron Health” or the “Company”, Nasdaq: GTH), a leading precision oncology platform company in China that specializes in offer...
Genetron Health to Announce First Quarter 2022 Unaudited Financial Results and Host Investor Call on June 2, 2022
BEIJING, May 23, 2022 (GLOBE NEWSWIRE) -- Genetron Holdings Limited (“Genetron Health” or the “Company”, NASDAQ: GTH), a leading precision oncology platform company in China that specializes in offeri...
Genetron Health Receives CE Mark for Human B Lymphocyte Minimal Residual Disease Detection Kit Seq-MRD®
BEIJING, April 19, 2022 (GLOBE NEWSWIRE) -- Genetron Holdings Limited (“Genetron Health” or the “Company”, Nasdaq: GTH), a leading precision oncology platform company in China that specializes in offe...
Genetron Health Presents 17 New Research Results at American Association for Cancer Research Annual Meeting (AACR) 2022
BEIJING, April 08, 2022 (GLOBE NEWSWIRE) -- Genetron Holdings Limited (“Genetron Health” or the “Company”, Nasdaq: GTH), a leading precision oncology platform company in China that specializes in offe...
Publication in Clinical and Translational Medicine Demonstrates Mutation Capsule™'s potential in MRD Assay Developments
BEIJING, April 07, 2022 (GLOBE NEWSWIRE) -- Genetron Holdings Limited (“Genetron Health” or the “Company”, NASDAQ: GTH), a leading precision oncology platform company in China that specializes in offe...
Genetron Health Announces Unaudited Fourth Quarter and Full Year 2021 Financial Results
BEIJING, March 29, 2022 (GLOBE NEWSWIRE) -- Genetron Holdings Limited (“Genetron Health” or the “Company”, NASDAQ: GTH), a leading precision oncology platform company in China that specializes in offe...
Arima Genomics Closes Series B Financing to Support Growing Portfolio of 3D Genomics Solutions for Biomedical Research and Translational Applications
SAN DIEGO--(BUSINESS WIRE)-- #3Dgenomics--Arima Genomics closes $7M series B financing to support continued growth of 3D genomics portfolio for research and translational applications.
Genetron Health to Announce Fourth Quarter and Full Year 2021 Unaudited Financial Results and Host Investor Call on March 29, 2022
BEIJING, March 09, 2022 (GLOBE NEWSWIRE) -- Genetron Holdings Limited (“Genetron Health” or the “Company”, NASDAQ: GTH), a leading precision oncology platform company in China that specializes in offe...
Genetron Health Announces Companion Diagnostic Collaboration Agreement with HUTCHMED's ORPATHYS® for NSCLC
BEIJING, Feb. 10, 2022 (GLOBE NEWSWIRE) -- Genetron Holdings Limited (“Genetron Health” or the “Company”, NASDAQ: GTH), a leading precision oncology platform company in China that specializes in offer...
Genetron Health to Participate in Upcoming Investor Conferences
BEIJING, Jan. 31, 2022 (GLOBE NEWSWIRE) -- Genetron Holdings Limited (“Genetron Health” or the “Company”, Nasdaq: GTH), a leading precision oncology platform company in China that specializes in offer...
Genetron Health Reiterates Full Year 2021 Revenue Guidance
BEIJING, Jan. 10, 2022 (GLOBE NEWSWIRE) -- Genetron Holdings Limited (“Genetron Health” or the “Company”, Nasdaq: GTH), a leading precision oncology platform company in China that specializes in offer...
Genetron Health's Social Contribution Campaign to Make Precision Medicine More Accessible
BEIJING, Dec. 13, 2021 (GLOBE NEWSWIRE) -- (“Genetron Health” or the “Company”, NASDAQ: GTH), a leading precision oncology platform company in China that specializes in offering molecular profiling te...
Genetron Health Reports Third Quarter 2021 Unaudited Financial Results
BEIJING, Nov. 30, 2021 (GLOBE NEWSWIRE) -- Genetron Holdings Limited (“Genetron Health” or the “Company”, NASDAQ: GTH), a leading precision oncology platform company in China that specializes in offer...
Genetron Health Announces Co-Development Agreement with AstraZeneca R&D China for Personalized MRD Tests for Solid Tumors in China
Collaboration highlights the value of MRD solid tumor data generated by Genetron's Mutation Capsule platform, and further accelerates product development Collaboration highlights the value of MRD soli...
Genetron Health Reveals Two Cancer Research Study Results at the Association for Molecular Pathology 2021 Annual Meeting
BEIJING, Nov. 16, 2021 (GLOBE NEWSWIRE) -- Genetron Holdings Limited (“Genetron Health” or the “Company”, NASDAQ: GTH), a leading precision oncology platform company in China that specializes in offer...